Obe-Cel Elicits High Remission Rates in R/R B-ALL Irrespective of Leukemic Burden
December 10th 2023Obecabtagene autoleucel elicited durable responses in patients with relapsed or refractory B-cell acute lymphoblastic leukemia independent of leukemic burden at lymphodepletion, although better outcomes were observed in those with lower burden.
Read More
Lenvatinib/Pembrolizumab/Chemo Is Safe With Early Efficacy Signals in mESCC
October 23rd 2023The combination of lenvatinib, pembrolizumab, and chemotherapy had a manageable safety profile and elicited preliminary antitumor activity in patients with metastatic esophageal squamous cell carcinoma.
Read More
Use of the novel T-charge rapid manufacturing platform for the production of durcabtagene autoleucel CAR T cells within 2 days was successful in producing rapid and robust in vivo expansion, as well as long-term T-cell persistence in patients with relapsed/refractory multiple myeloma, according to a correlative analysis of data from an ongoing phase 1 trial presented at the 2023 IMS Annual Meeting.
Read More
Fianlimab/Cemiplimab Demonstrates Early Clinical Activity and Safety in Advanced Melanoma
June 6th 2023The LAG-3 inhibitor fianlimab plus cemiplimab produced high and consistent tumor responses and a comparable toxicity profile to that of anti–PD-L1 monotherapies in patients with advanced melanoma who were PD-L1 inhibitor–naïve in the advanced setting, according to data from a phase 1 study.
Read More
BRCA Mutations Associated with Worse Survival in HRR-deficient mCRPC
June 4th 2023Patients with homologous recombination repair–deficient mutations and metastatic castration-resistant prostate cancer who also harbored BRCA mutations experienced poorer survival outcomes vs patients without BRCA mutations and those with non-BRCA HRR mutations, according to an analysis from the CAPTURE trial.
Read More
Ruxolitinib Displays Variable Pharmacokinetics in Patients with GVHD 2 Years of Age and Under
February 17th 2023A study did not find a correlation between the pharmacokinetics and pharmacodynamics of ruxolitinib for the treatment of patients 2 years of age and younger with graft-vs-host disease.
Read More
MRD Detection Provides Prognostic Value in Patients With ALL Undergoing HCT
February 16th 2023The presence of minimal residual disease led to a higher likelihood of relapse in patients with acute lymphoblastic leukemia who underwent hematopoietic cell transplant compared with those who had undetectable MRD pre and post transplant.
Read More
Trastuzumab Deruxtecan at Reduced Dose Maintains Efficacy in HER2-Mutated NSCLC
September 12th 2022The clinical benefit and tolerable safety profile of trastuzumab deruxtecan was maintained at 5.4 kg/mg vs 6.4 kg/mg in patients with HER2-mutated non–small cell lung cancer, confirming the benefit-risk ratio of the FDA-approved dose.
Read More
Isatuximab Plus Carfilzomib/Dexamethasone Maintains Survival Benefit in Relapsed Multiple Myeloma
August 26th 2022The combination of Isatuximab plus carfilzomib and dexamethasone continued to demonstrate a progression-free survival benefit vs carfilzomib and dexamethasone alone in relapsed multiple myeloma.
Read More
Larotrectinib Demonstrates Favorable Long-Term Responses in NTRK Fusion–Positive Lung Cancer
August 6th 2022Larotrectinib continued to elicit durable responses and a low toxicity profile in patients with NTRK fusion–positive lung cancer, according to long-term follow-up data from the phase 2 NAVIGATE trial and phase 1 LOXO-TRK-14001 trial.
Read More
Panitumumab Plus Intensified Chemotherapy Fails to Improve Efficacy in mCRC
June 7th 2022The EGFR inhibitor panitumumab plus a stronger chemotherapy regimen did not demonstrate a significant response benefit over an active chemotherapy comparator plus panitumumab in patients with metastatic colorectal cancer with unmutated RAS and BRAF.
Read More
Nivolumab/Ipilimumab Demonstrated Long-term Efficacy in Metastatic NSCLC
June 6th 2022Results of a 5-year analysis of the phase 3 CheckMate 227 trial showed that the combination of nivolumab plus ipilimumab elicited durable overall survival benefit in patients with metastatic non–small cell lung cancer regardless of PD-L1 expression compared with chemotherapy.
Read More
Darolutamide Added to ADT/Docetaxel Shows No Increased Toxicity in mHSPC
May 16th 2022The combination of darolutamide plus androgen deprivation therapy and docetaxel presents adverse effects that are similar to those experienced with ADT plus docetaxel alone in patients with metastatic hormone-sensitive prostate cancer.
Read More
Topical Ruxolitinib Shown to be Effective and Tolerable in Cutaneous cGVHD
April 25th 2022Topical ruxolitinib has shown improved reduction of body surface area of cutaneous chronic graft-vs-host disease vs standard moisturizer vehicle cream, according to interim study results from a poster presented at the 2022 Transplantation & Cellular Therapy Meetings.
Read More